公开(公告)号：WO2017139468A1

公开(公告)日：2017-08-17

申请号：PCT/US2017/017193

申请日：2017-02-09

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  TSUCHIYA, Hiromichi ,  RUNKLE, Aaron

Inventor： TSUCHIYA, Hiromichi ,  RUNKLE, Aaron ,  GREENE, Mark ,  ZHANG, Hongtao ,  NAGAI, Yasuhiro ,  LAM, Lian ,  DREBIN, Jeffrey ,  JI, Mei Qing

IPC: A61K38/21 ,  A61K39/395

CPC classification number: C07K16/3076 ,  A61K31/337 ,  A61K31/517 ,  A61K38/02 ,  A61K38/21 ,  A61K38/217 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/70 ,  C07K2319/75 ,  A61K2300/00

Abstract: The present invention provides methods and compositions treating or preventing cancer and for sensitizing cancer cells to radiation or a chemotherapeutic agent, which comprises administering i) an erbB inhibitor; and ii) interferon-gamma (IFN ).

Abstract translation: 本发明提供治疗或预防癌症和使癌细胞对辐射敏感的方法和组合物或化学治疗剂，其包括施用i）erbB抑制剂; 和ii）干扰素-γ（IFN）。

公开(公告)号：WO2016077526A1

公开(公告)日：2016-05-19

申请号：PCT/US2015/060287

申请日：2015-11-12

Applicant: SIAMAB THERAPEUTICS, INC.

Inventor： DA SILVA, Ana Paula Galvao ,  GHADERI, Darius ,  ZHANG, Mai ,  PURNAJO, Intan ,  MEETZE, Kristan ,  DESANDER, Julie ,  BEHRENS, Jeffrey ,  EAVARONE, David A. ,  PRENDERGAST, Jillian M. ,  LUGOVSKOY, Alexey Alexandrovich

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/00

CPC classification number: G01N33/57492 ,  A61K47/48438 ,  A61K47/48569 ,  C07K16/005 ,  C07K16/3076 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.

Abstract translation: 本发明提供了聚糖相互作用的抗体和用于生产可用于治疗和预防人类疾病（包括癌症）的聚糖相互作用的抗体的方法。 这样的聚糖相互作用抗体包括单克隆抗体，衍生物及其片段，以及包含它们的组合物和试剂盒。 还提供了使用聚糖相互作用抗体靶向细胞并治疗疾病的方法。

公开(公告)号：WO2015173249A1

公开(公告)日：2015-11-19

申请号：PCT/EP2015/060491

申请日：2015-05-12

Applicant: F. HOFFMANN-LA ROCHE AG ,  HOFFMANN-LA ROCHE INC.

Inventor： BOSSENMAIER, Birgit ,  GERG, Michael ,  NIEDERFELLNER, Gerhard ,  SCHRAEML, Michael ,  PEESS, Carmen

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/3076 ,  A61K2039/505 ,  A61K2039/6068 ,  C07K14/71 ,  C07K16/2863 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/77 ,  G01N33/6854

Abstract: The disclosure relates to anti-HERI antigen binding proteins, e.g. anti-HERI antibodies, that bind to the beta-hairpin of HER1, methods for selecting these antigen binding proteins, their preparation and use as medicament.

Abstract translation: 本公开涉及抗HERI抗原结合蛋白，例如 结合HER1的β-发夹的抗HERI抗体，选择这些抗原结合蛋白的方法，其制备和用作药物。

公开(公告)号：WO2015053871A4

公开(公告)日：2015-07-30

申请号：PCT/US2014052631

申请日：2014-08-26

Applicant: MABVAX THERAPEUTICS INC

Inventor： SAWADA RITSUKO ,  SUN SHU-MAN ,  SCHOLZ WOLFGANG

IPC: A61K39/395 ,  C07K16/30 ,  C12N15/13

CPC classification number: C07K16/2896 ,  A61K31/337 ,  A61K39/0011 ,  A61K39/39533 ,  A61K39/39558 ,  A61K45/06 ,  A61K51/1027 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1093 ,  A61K2039/505 ,  A61K2039/6081 ,  C07K16/28 ,  C07K16/3076 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/626 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/57438 ,  G01N33/577

Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa (sLea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.

公开(公告)号：WO2015099548A1

公开(公告)日：2015-07-02

申请号：PCT/PL2014/050080

申请日：2014-12-29

Applicant: INSTYTUT IMMUNOLOGII I TERAPII DOŚWIADCZALNEJ PAN ,  UNIWERSYTET MEDYCZNY IM. PIASTÓW ŚLĄSKICH WE WROCŁAWIU

Inventor： KORZENIOWSKA-KOWAL, Agnieszka ,  KOCHMAN, Agata ,  ZIÓŁKOWSKI, Piotr ,  GAMIAN, Andrzej

IPC: C07K16/12 ,  C07K16/18 ,  C07K16/30 ,  A61P35/00

CPC classification number: C07K16/1232 ,  C07K14/245 ,  C07K16/18 ,  C07K16/3076 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/92 ,  G01N33/56911 ,  G01N2400/50 ,  G01N2469/10

Abstract: We disclose the use of bacterial antigens and obtained antibodies. The resulting antibodies can be used in the diagnosis of tumors by immunohistochemistry and in the binding of drugs to antibodies for use in cancer therapy.

Abstract translation: 我们公开了使用细菌抗原和获得的抗体。 所得抗体可用于通过免疫组织化学和药物与用于癌症治疗的抗体的结合来诊断肿瘤。

公开(公告)号：WO2014033298A3

公开(公告)日：2015-06-11

申请号：PCT/EP2013068101

申请日：2013-09-02

Applicant: VIB VZW ,  LIFE SCIENCES RES PARTNERS VZW ,  UNIV LEUVEN KATH

Inventor： MAZZONE MASSIMILIANO ,  FINISGUERRA VERONICA

IPC: A61K31/501 ,  A61K31/00 ,  C07K16/28

CPC classification number: A61K39/39558 ,  A61K38/191 ,  A61K45/06 ,  C07K16/2863 ,  C07K16/3076 ,  C07K2317/24 ,  C07K2317/76

Abstract: The present application relates to granulocytes and their role in both cancer and inflammation. More particularly, it was found that c-Met expressed by granulocytes is important in transmigration and recruitment of the granulocytes. It is shown that reducing c-Met-mediated transmigration of granulocytes sustains tumor progression, indicating that c-Met-mediated granulocyte transmigration should actually be maintained because it is beneficial in treatment of cancers, particularly cancers that otherwise show resistance to c-Met inhibition. Reducing c-Met-mediated transmigration on the other hand is particularly useful in conditions characterized by an excessive immune response, such as asthma.

Abstract translation: 本申请涉及粒细胞及其在癌症和炎症中的作用。 更具体地，发现由粒细胞表达的c-Met在粒细胞的迁移和募集中是重要的。 显示减少c-Met介导的粒细胞迁移维持肿瘤进展，表明c-Met介导的粒细胞迁移实际上应该保持，因为它有利于治疗癌症，特别是否则显示出对c-Met抑制的抗性的癌症 。 另一方面，减少c-Met介导的迁移在特征为过度免疫应答（如哮喘）的病症中特别有用。

公开(公告)号：WO2013188740A1

公开(公告)日：2013-12-19

申请号：PCT/US2013/045834

申请日：2013-06-14

Applicant: AMBRX, INC.

Inventor： SUN, Ying ,  ZOU, Ning ,  HEWET, Amha ,  PINKSTAFF, Jason, K. ,  SRINAGESH, Shailaja ,  BARNETT, Richard, S. ,  TIAN, Feng ,  PUTNAM, Anna-Maria, A. Hays ,  GYMNOPOULOS, Marco ,  KNUDSEN, Nick ,  BECK, Andrew

IPC: A61K47/48 ,  C07K16/30

CPC classification number: C07K16/3076 ,  A61K47/6869 ,  C07K16/3069

Abstract: This invention relates to anti-prostate-specific membrane antigen antibodies (αPSMA) and αPSMA antibody - nuclear receptor ligand (NRL) conjugates comprising at least one non-naturally-encoded amino acid.

Abstract translation: 本发明涉及包含至少一种非天然编码氨基酸的抗前列腺特异性膜抗原抗体（αPSMA）和αPSMA抗体 - 核受体配体（NRL）缀合物。

公开(公告)号：WO2011110642A3

公开(公告)日：2012-07-05

申请号：PCT/EP2011053646

申请日：2011-03-10

Applicant: GENMAB AS ,  NEIJSSEN JOOST J ,  DE GOEIJ BART ,  VAN DEN BRINK EDWARD ,  LABRIJN ARAN FRANK ,  HOET RENE M A ,  SCHUURMAN JANINE ,  PARREN PAUL ,  VAN DE WINKEL JAN

Inventor： NEIJSSEN JOOST J ,  DE GOEIJ BART ,  VAN DEN BRINK EDWARD ,  LABRIJN ARAN FRANK ,  HOET RENE M A ,  SCHUURMAN JANINE ,  PARREN PAUL ,  VAN DE WINKEL JAN

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/3076 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5748 ,  G01N2333/912

Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Abstract translation: 公开了结合人c-Met，肝细胞生长因子受体以及相关的基于抗体的组合物和分子的分离的单克隆抗体。 还公开了包含抗体的药物组合物和使用抗体的治疗和诊断方法。

公开(公告)号：WO2010002478A2

公开(公告)日：2010-01-07

申请号：PCT/US2009/003944

申请日：2009-07-02

Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. ,  BOONS, Geert-Jan ,  BUSKAS, Therese ,  INGALE, Sampat ,  WOLFERT, Margaretha

Inventor： BOONS, Geert-Jan ,  BUSKAS, Therese ,  INGALE, Sampat ,  WOLFERT, Margaretha

IPC: C07K19/00 ,  C07K14/435 ,  C07K16/18 ,  A61K38/17 ,  G01N33/53 ,  G01N33/68

CPC classification number: C07K16/44 ,  A61K9/127 ,  A61K38/00 ,  A61K39/0008 ,  A61K39/0011 ,  A61K47/646 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/57 ,  A61K2039/6018 ,  A61K2039/6075 ,  C07K9/00 ,  C07K14/22 ,  C07K14/4727 ,  C07K16/3076 ,  C07K2317/34 ,  C12N2740/16011 ,  C12N2740/16134 ,  G01N33/92 ,  G01N2400/02 ,  G01N2800/042 ,  G01N2800/2821

Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.

Abstract translation: 包含用作治疗或预防性疫苗的碳水化合物组分，肽组分和脂质组分的糖脂肽。 还提供了识别本发明的糖脂肽的单克隆和多克隆抗体及其用途。

公开(公告)号：WO2009079649A1

公开(公告)日：2009-06-25

申请号：PCT/US2008/087515

申请日：2008-12-18

Applicant: BIOALLIANCE C.V. ,  LIN, Shih-Yao ,  LIN, Leewen ,  TSAI, Yu-Ying

Inventor： LIN, Shih-Yao ,  LIN, Leewen ,  TSAI, Yu-Ying

IPC: C07K16/28 ,  C07K16/30

CPC classification number: C07K16/2896 ,  C07K16/3007 ,  C07K16/3076 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/73

Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.

Abstract translation: 本发明提供抗体（例如嵌合和人源化抗体）特异性结合在非造血癌细胞上表达的CD43和CEA上的表位。 此外，本发明还提供本文所述的抗体用于诊断和治疗目的的用途。